Immunovia AB Stock: price and insider trades · Sweden
No insider purchase over the last 90 days. The latest, by Hans Johansson, was filed 03 Nov 2025.
Immunovia AB: what insiders have been doing
Immunovia AB is a listed company. Its insiders report their share dealings to Finansinspektionen. From 24 October 2025 to 24 October 2026, the disclosure feed for Immunovia AB logged 1 filing by 1 insider.
Every open-market trade in the period is a purchase: 1 purchase worth €7,954, from 1 insider, and not a single sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. One trade stands out by size: a purchase of €7,954 from Hans Johansson, disclosed on 3 November 2025. The buyers include 1 board member.
Compared with its exchange (1,028 companies, median 9 filings), a count of 1 filing is below the norm. Our records for Immunovia AB go back to 2016, with 35 purchases and 20 sales on the open market in total.
The last insider purchase was made public on 3 November 2025, 370 days ago.
In the same market, recent insider purchases at Dynavox Group AB and Rusta AB (publ) also feature in our signals. Source: insider filings from Finansinspektionen. Past trades are no guide to future returns.
Who traded when
BuySale- 289,698 shares@ SEK 0.30BTA (betald tecknad aktie)ISIN SE0019913559FI:csv-2e3781981d1a5917f0a9Canonical exit: 29 Jan 2026 (T+90)
- 2,500 shares@ SEK 117.00100.0% of flowAktieISIN SE0006091997FI:csv-26fd219e13a2f41bede7Canonical exit: 2 Mar 2021 (T+90)
- 1,000 shares@ SEK 144.2023.8% of flowAktieISIN SE0006091997FI:csv-736f494f8d799c2f72f1Canonical exit: 1 Mar 2021 (T+90)
- 500 shares@ SEK 144.80100.0% of flowAktieISIN SE0006091997FI:csv-4ee98752ab1e2805b238Canonical exit: 1 Mar 2021 (T+90)
- 500 shares@ SEK 161.00100.0% of flowAktieISIN SE0006091997FI:csv-7a6389a360eb25dea639Canonical exit: 28 Jan 2021 (T+90)
- 15,000 shares@ SEK 168.08100.0% of flowAktieISIN SE0006091997FI:csv-4a24ba355bdc8887c3ffCanonical exit: 15 Feb 2021 (T+90)
- 5,082 shares@ SEK 98.47100.0% of flowAktieISIN SE0006091997FI:csv-6971b805d6b95021fadeCanonical exit: 22 Jun 2020 (T+90)
- 10,000 shares@ SEK 145.0056.5% of flowAktieISIN SE0006091997FI:csv-121e05b5e5f9d6ddd5c7
- 50,000 shares@ SEK 82.9029.6% of flowAktieISIN SE0006091997FI:csv-26cca21ccfd1b6cdd358Canonical exit: 18 Dec 2019 (T+90)
- 35,000 shares@ SEK 145.0036.4% of flowAktieISIN SE0006091997FI:csv-67200d5f5460c026762c
- 2,000 shares@ SEK 6.950.2% of flowTeckningsoptionFI:csv-6b93e7988c5240c6c74fCanonical exit: 18 Dec 2019 (T+90)
- 30,000 shares@ SEK 82.9028.8% of flowAktieISIN SE0006091997FI:csv-52000f46167f1106a51eCanonical exit: 18 Dec 2019 (T+90)
- 20,000 shares@ SEK 145.0033.6% of flowAktieISIN SE0006091997FI:csv-32dca00b5284d2c97f5e
- 2,000 shares@ SEK 6.950.5% of flowTeckningsoptionFI:csv-3fb7caa3db2de850db3bCanonical exit: 18 Dec 2019 (T+90)
- 2,000 shares@ SEK 6.950.1% of flowTeckningsoptionFI:csv-b649f0cb8a8cea42f45cCanonical exit: 18 Dec 2019 (T+90)
- 4,000 shares@ SEK 6.9558.7% of flowTeckningsoptionFI:csv-a4a2afd8cbc9ed5c584fCanonical exit: 11 Dec 2019 (T+90)
- 2,000 shares@ SEK 6.950.1% of flowTeckningsoptionFI:csv-e726154eeed19a5db216Canonical exit: 11 Dec 2019 (T+90)
- 2,000 shares@ SEK 6.950.1% of flowTeckningsoptionFI:csv-8d646d5feabc5ac89a13Canonical exit: 11 Dec 2019 (T+90)
- 2,500 shares@ SEK 7.7741.3% of flowTeckningsoptionFI:csv-b5bc1b839f0d3824a447Canonical exit: 28 Sept 2019 (T+90)
- 5,000 shares@ SEK 7.770.3% of flowTeckningsoptionFI:csv-51eacc09e1ca06b15b77Canonical exit: 28 Sept 2019 (T+90)
- 17,500 shares@ SEK 7.771.1% of flowTeckningsoptionFI:csv-e0279c62aeaefa9179b1Canonical exit: 28 Sept 2019 (T+90)
- 17,500 shares@ SEK 7.7770.0% of flowTeckningsoptionFI:csv-49835875177c55284a53
- 5,000 shares@ SEK 7.7720.0% of flowTeckningsoptionFI:csv-8ba7a8c567a2b88016a4
- 2,500 shares@ SEK 7.7710.0% of flowTeckningsoptionFI:csv-323023b4a8858e959056
- 48,000 shares@ SEK 168.0064.8% of flowAktieISIN SE0006091997FI:csv-890a17f0d71dc7938b43
25 of 56 declarations
About Immunovia AB
Immunovia AB is a Swedish company focused on developing diagnostic tests for cancer. It aims to improve early disease detection through the use of biomarkers.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations